Meeting
2019 ASCO Annual Meeting
First-in-human phase 1 study of the antibody-drug conjugate (ADC) SAR408701 in advanced solid tumors: Dose-expansion cohort of patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC).
Authors
Anas Gazzah
Department of Drug Development (DITEP), Gustave Roussy, Villejuif Cedex, France
Anas Gazzah , Sophie Cousin , Valentina Boni , Charles Ricordel , Tae Min Kim , Jin-Soo Kim , Carole Helissey , Itziar Gardeazabal , Mustapha Chadjaa , Aurore Allard , Semra Yoruk , Fabrice Barlesi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02187848
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9072)
DOI
10.1200/JCO.2019.37.15_suppl.9072
Abstract #
9072
Poster Bd #
395
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
First Author: Mohamed Shanshal
Poster
2023 ASCO Annual Meeting
Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.
First Author: Gottfried E. Konecny
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2020 ASCO Virtual Scientific Program
Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC).
First Author: Aaron Elliott Lisberg